Table of Contents Author Guidelines Submit a Manuscript
International Journal of Vascular Medicine
Volume 2010, Article ID 390643, 8 pages
http://dx.doi.org/10.1155/2010/390643
Review Article

Mesoglycan: Clinical Evidences for Use in Vascular Diseases

Regional Reference Centre for Coagulation Disorders, Department of Clinical and Experimental Medicine, AOU “Federico II” Naples 80131, Italy

Received 1 March 2010; Revised 4 June 2010; Accepted 12 July 2010

Academic Editor: Alun H. Davies

Copyright © 2010 Antonella Tufano et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Vittoria, G. L. Messa, C. Frigerio, G. Celasco, and A. Auteri, “Effect of a single dose of mesoglycan on the human fibrinolytic system, and the profibrinolytic action of nine daily doses,” International Journal of Tissue Reactions, vol. 10, no. 4, pp. 261–266, 1988. View at Google Scholar · View at Scopus
  2. A. Maggi, M. Abbadini, P. G. Pagella, A. Borowska, J. Pangrazzi, and M. B. Donati, “Antithrombotic properties of dermatan sulphate in a rat venous thrombosis model,” Haemostasis, vol. 17, no. 6, pp. 329–335, 1987. View at Google Scholar · View at Scopus
  3. A. N. Teien, U. Abildgaard, and M. Hook, “The anticoagulant effect of heparin sulfate and dermatan sulfate,” Thrombosis Research, vol. 8, no. 6, pp. 859–867, 1976. View at Google Scholar · View at Scopus
  4. M. Abbadini, G. J. Zhu, A. Maggi, J. Pangrazzi, M. B. Donati, and L. Mussoni, “Dermatan sulphate induces plasminogen activator release in the perfused rat hindquarters,” Blood, vol. 70, no. 6, pp. 1858–1860, 1987. View at Google Scholar · View at Scopus
  5. G. Restori, L. Boiardi, S. Mari et al., “Glycosaminoglycans administration (heparan sulphate, dermatan-sulphate and their combinations 50:50) and reduction of atherosclerosis progression rate in rabbits with a diet-induced hypercholesterolemia,” Atherosclerosis and Cardiovascular Disease, vol. 4, pp. 971–975, 1989. View at Google Scholar
  6. M. A. Blajchman, E. Young, and F. A. Ofosu, “Effects of unfractionated heparin, dermatan sulfate and low molecular weight heparin on vessel wall permeability in rabbits,” Annals of the New York Academy of Sciences, vol. 556, pp. 245–254, 1989. View at Google Scholar · View at Scopus
  7. G. Caimi, S. Romandini, R. Lo Presti et al., “Effect of mesoglycan on macrorheologic and microrheologic parameters,” Current Therapeutic Research, vol. 52, no. 3, pp. 412–418, 1992. View at Google Scholar · View at Scopus
  8. T. Viliani, M. Scarselli, A. Pieri, M. Gatti, M. Santini, and P. Pasquetti, “Pharmacological treatment of mechanical edema: a randomized controlled trial about the effects of mesoglycan,” European Journal of Physical and Rehabilitation Medicine, vol. 45, no. 1, pp. 21–29, 2009. View at Google Scholar · View at Scopus
  9. M. Tardieu, M.-C. Bourin, P. Desgranges, P. Barbier, D. Barritault, and J.-P. Caruelle, “Mesoglycan and sulodexide act as stabilizers and protectors of fibroblast growth factors (FGFs),” Growth Factors, vol. 11, no. 4, pp. 291–300, 1994. View at Google Scholar · View at Scopus
  10. T. Lotti, G. Celasco, D. Tsampau et al., “Mesoglycan treatment restores defective fibrinolytic potential in cutaneous necrotizing venulitis,” International Journal of Dermatology, vol. 32, no. 5, pp. 368–371, 1993. View at Google Scholar · View at Scopus
  11. G. Orefice, V. Brancaccio, G. Coppola et al., “Comparative effects of mesoglycan and ticlopidine treatment on some coagulative parameters in patients with previous ischemic stroke: results of a randomized controlled trial,” Current Therapeutic Research, vol. 63, no. 5, pp. 337–343, 2002. View at Publisher · View at Google Scholar · View at Scopus
  12. G. Orefice, E. Troisi, M. Selvaggio et al., “Effect of long-term mesoglycan treatment on fibrinogen plasma levels in patients with ischemic cerebrovascular disease,” Current Therapeutic Research, vol. 52, no. 5, pp. 666–670, 1992. View at Publisher · View at Google Scholar · View at Scopus
  13. F. Vecchio, G. Zanchin, F. Maggioni, C. Santambrogio, and L. De Zanche, “Mesoglycan in treatment of patients with cerebral ischemia: effects of hemorheologic and hematochemical parameters,” Acta Neurologica, vol. 48, no. 6, pp. 449–456, 1993. View at Google Scholar · View at Scopus
  14. D. Mansi, L. Sinisi, G. De Michele et al., “Open trial of mesoglycan in the treatment of cerebrovascular ischemic disease,” Acta Neurologica, vol. 43, no. 2, pp. 108–112, 1988. View at Google Scholar · View at Scopus
  15. S. Forconi, N. Battistini, N. Guerrini, and G. S. Passero, “A randomized, ASA-controlled trial of mesoglycan in secondary prevention after cerebral ischemic events,” Cerebrovascular Diseases, vol. 5, pp. 334–341, 1995. View at Publisher · View at Google Scholar
  16. L. Wilhelmsen, K. Svardsudd, and K. Korsan-Bengtsen, “Fibrinogen as a risk factor for stroke and myocardial infarction,” The New England Journal of Medicine, vol. 311, no. 8, pp. 501–505, 1984. View at Google Scholar · View at Scopus
  17. G. Di Minno and M. Mancini, “Drugs affecting plasma fibrinogen levels,” Cardiovascular Drugs and Therapy, vol. 6, no. 1, pp. 25–27, 1992. View at Publisher · View at Google Scholar · View at Scopus
  18. G. M. Andreozzi, S. Signorelli, S. Lo Duca et al., “Effects of mesoglycan sulfate on the arterial elastic module,” Angiology, vol. 38, no. 8, pp. 593–600, 1987. View at Google Scholar · View at Scopus
  19. A. M. Raso, D. Maggio, M. Trogolo et al., “Effectiveness of mesoglycan therapy in patients with ischemia of the lower limbs. Preliminary results of a new therapeutic protocol,” Minerva Cardioangiologica, vol. 45, no. 7-8, pp. 383–392, 1997. View at Google Scholar
  20. G. G. Nenci, P. Gresele, G. Ferrari, L. Santoro, and F. Gianese, “Treatment of intermittent claudication with mesoglycan—a placebo-controlled, double-blind study,” Thrombosis and Haemostasis, vol. 86, no. 5, pp. 1181–1187, 2001. View at Google Scholar · View at Scopus
  21. Y. Nakashima, J. Segawa, T. Kawashima, Y. Fukuchi, and A. Kuroiwa, “Chronic arterial occlusion with PGE1-resistant skin lesions treated by glycosaminoglycan compound—case reports,” Angiology, vol. 41, no. 9, pp. 731–736, 1990. View at Google Scholar · View at Scopus
  22. J. Segawa, T. Kawashima, A. Yashiro et al., “Acute effects of intravenous administration of glycosaminoglycans compound (FPFD 101) on healthy volunteers,” Journal of Japan Atherosclerosis Society, vol. 16, p. 871, 1988. View at Google Scholar
  23. E. Arosio, G. Ferrari, L. Santoro, and F. Gianese, “A placebo-controlled, double-blind study of mesoglycan in the treatment of chronic venous ulcers,” European Journal of Vascular and Endovascular Surgery, vol. 22, no. 4, pp. 365–372, 2001. View at Publisher · View at Google Scholar · View at Scopus
  24. G. M. Andreozzi, “Effectiveness of mesoglycan in patients with previous deep venous thrombosis and chronic venous insufficiency,” Minerva Cardioangiologica, vol. 55, no. 6, pp. 741–753, 2007. View at Google Scholar · View at Scopus
  25. T. Viliani, M. Scarselli, A. Pieri, M. Gatti, M. Santini, and P. Pasquetti, “Pharmacological treatment of mechanical edema: a randomized controlled trial about the effects of mesoglycan,” European Journal of Physical and Rehabilitation Medicine, vol. 45, no. 1, pp. 21–29, 2009. View at Google Scholar · View at Scopus
  26. P. Prandoni, A. M. Cattelan, and M. Carta, “Long-term sequelae of deep-vein thrombosis of the lower limbs. Experience with mesoglycan,” Annali Italiani di Medicina Interna, vol. 4, no. 4, pp. 378–385, 1989. View at Google Scholar · View at Scopus
  27. X. Kurz, S. R. Kahn, L. Abenhaim et al., “Chronic venous disorders of the leg: epidemiology, outcomes, diagnosis and management. Summary of an evidence-based report of the VEINES task force. Venous Insufficiency Epidemiologic and Economic Studies,” International Angiology, vol. 18, no. 2, pp. 83–102, 1999. View at Google Scholar
  28. M. van de Scheur and V. Falanga, “Pericapillary fibrin cuffs in venous disease: a reappraisal,” Dermatologic Surgery, vol. 23, no. 10, pp. 955–959, 1997. View at Google Scholar · View at Scopus
  29. S. F. Penc, B. Pomahac, T. Winkler et al., “Dermatan sulfate released after injury is a potent promoter of fibroblast growth factor-2 function,” Journal of Biological Chemistry, vol. 273, no. 43, pp. 28116–28121, 1998. View at Publisher · View at Google Scholar · View at Scopus
  30. J. A. McGrath and R. A. J. Eady, “Heparan sulphate proteoglycan and wound healing in skin,” Journal of Pathology, vol. 183, no. 3, pp. 251–252, 1997. View at Publisher · View at Google Scholar · View at Scopus
  31. F. Mariani, “Edema of the lower limb: differential diagnosis and therapy,” Italian Journal of Practice Cardiology, vol. 2, pp. 61–69, 2004. View at Google Scholar
  32. M. Terry, S. P. O'Brien, and M. D. Kerstein, “Lower-extremity edema: evaluation and diagnosis,” Wounds, vol. 10, no. 4, pp. 118–124, 1998. View at Google Scholar · View at Scopus
  33. F. T. Padberg Jr., M. V. Johnston, S. A. Sisto, K. G. Burnand, T. W. Wakefield, and P. Perkowski, “Structured exercise improves calf muscle pump function in chronic venous insufficiency: a randomized trial,” Journal of Vascular Surgery, vol. 39, no. 1, pp. 79–87, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. S. Coccheri, G. Scondotto, G. Agnelli, D. Aloisi, E. Palazzini, and V. Zamboni, “Randomised, double blind, multicentre, placebo controlled study of sulodexide in the treatment of venous leg ulcers,” Thrombosis and Haemostasis, vol. 87, no. 6, pp. 947–952, 2002. View at Google Scholar · View at Scopus
  35. C. Kearon, S. R. Kahn, G. Agnelli, S. Goldhaber, G. E. Raskob, and A. J. Comerota, “Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition),” Chest, vol. 133, no. 6, pp. 454S–545S, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. R. Pesavento, S. Villalta, and P. Prandoni, “The post-thrombotic syndrome,” Internal and Emergency Medicine, vol. 5, no. 3, pp. 185–192, 2010. View at Google Scholar